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a b s t r a c t
The human T-cell leukemia retrovirus type-1 (HTLV-1) p30II protein is a multifunctional latency-
maintenance factor that negatively regulates viral gene expression and deregulates host signaling
pathways involved in aberrant T-cell growth and proliferation. We have previously demonstrated that
p30II interacts with the c-MYC oncoprotein and enhances c-MYC-dependent transcriptional and
oncogenic functions. However, the molecular and biochemical events that mediate the cooperation
between p30II and c-MYC remain to be completely understood. Herein we demonstrate that p30II
induces lysine-acetylation of the c-MYC oncoprotein. Acetylation-defective c-MYC Lys-Arg substitution
mutants are impaired for oncogenic transformation with p30II in c-myc / HO15.19 ﬁbroblasts. Using
dual-chromatin-immunoprecipitations (dual-ChIPs), we further demonstrate that p30II is present in
c-MYC-containing nucleoprotein complexes in HTLV-1-transformed HuT-102 T-lymphocytes. Moreover,
p30II inhibits apoptosis in proliferating cells expressing c-MYC under conditions of genotoxic stress.
These ﬁndings suggest that c-MYC-acetylation is required for the cooperation between p30II/c-MYC
which could promote proviral replication and contribute to HTLV-1-induced carcinogenesis.
& 2014 Elsevier Inc. All rights reserved.
Introduction
The HTLV-1 is a complex oncoretrovirus that infects CD4þ
T-lymphocytes and causes adult T-cell leukemia/lymphoma (ATLL)
–an aggressive and often fatal hematological malignancy that is
resistant to most anticancer treatments (Johnson et al., 2001;
Kannian and Green., 2010; Giam and Jeang., 2007). Similar to other
transforming viruses, such as Epstein-Barr virus (EBV), hepatitis B
and C viruses (HBV and HCV), human papillomavirus (HPV), and
Kaposi sarcoma herpesvirus/human herpesvirus-8 (KSHV/HHV-8),
the HTLV-1 induces viral latency associated with the establishment
of persistent long-term infections which can lead to the develop-
ment of malignant disease (Lairmore et al., 2011, 2012; Jeang, 2011;
Cesarman and Mesri, 2007; Chen et al., 2013). Importantly, the
mechanisms by which HTLV-1 deregulates host signaling pathways
and gene expression to promote aberrant T-cell lymphoproliferation
are not yet completely deﬁned. The HTLV-1 provirus encodes at
least seven regulatory/nonstructural and accessory proteins (Tax,
Rex, p8I, p12I, p13II, p30II, HBZ) within a highly conserved 30
nucleotide sequence, known as pX (Koralnik et al., 1993; Nicot et
al., 2005; Cereseto et al., 1997; Edwards et al., 2011; Silic-Benussi et
al., 2010; Bai and Nicot, 2012; Van Prooyen et al., 2010; Ma et al.,
2013; Arnold et al., 2006). The Tax transactivator protein interacts
with cellular transcription factors (CREB/ATF-1, NF-kappaB, and
SRFp67, p300/CREB-binding protein and the p300/CBP-associated
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factor) and regulates the expression of proviral and cellular genes
(Harrod et al., 1998, 2000; Tang et al., 1998; ; Nicot and Harrod, 2000;
Currer et al., 2012; Ho et al., 2012; Zhao and Giam,1992; Georges et al.,
2003; Wu and Sun, 2007; Zane et al., 2012). While Tax is generally
considered to be the major oncoprotein of HTLV-1 involved in early T-
cell immortalization and leukemic transformation, the HTLV-1 basic
domain/leucine zipper (HBZ) protein could also contribute to retroviral
carcinogenesis (Ma et al., 2013; Arnold et al., 2006, 2008; Zhi et al.,
2011; Zhao et al., 2011, 2013; Kuhlmann et al., 2007; Matsuoka and
Jeang, 2007; Satou et al., 2006). The HBZ product is translated from an
antisense pX transcript made from the 30 long-terminal repeat (LTR;
Matsuoka and Jeang, 2007; Satou et al., 2006), and has been shown to
induce expression of the human telomerase reverse transcriptase
(hTERT) gene through the activation of JunD, associated with aberrant
T-cell lymphoproliferation and immortalization (Kuhlmann et al.,
2007; Matsuoka and Jeang, 2007; Satou et al., 2006). Zhi et al.
(2011) have demonstrated that HBZ counters Tax-induced cellular
senescence by inhibiting NF-kappaB activation. Moreover, HBZ-
expressing transgenic mice exhibit systemic inﬂammation, particu-
larly, of the skin and lungs, and develop T-cell lymphomas (Satou et
al., 2011). In addition to these ﬁndings, we have previously demon-
strated that the p30II accessory protein cooperates with the c-MYC
oncoprotein and activates c-MYC dependent transcription –asso-
ciated with increased S-phase cell-cycle entry, multinucleation, and
oncogenic transformation/foci-formation by p30II/c-MYC (Awasthi
et al., 2005).
The HTLV-1 encodes three latency-maintenance factors: p30II, HBZ,
and p13II (Johnson et al., 2001; Kannian and Green, 2010; Lairmore
et al., 2012; Nicot et al., 2005; Edwards et al., 2011; Silic-Benussi et al.,
2010; Bai and Nicot, 2012; Arnold et al., 2006; Awasthi et al., 2005;
Li et al., 2009; Bai et al., 2010; Anupam et al., 2013; Michael et al.,
2006; Zhang et al., 2000, 2001; Nicot et al., 2004; Younis et al., 2004,
2006; Bartoe et al., 2000; Silverman et al., 2004; Clerc et al., 2008;
Lemasson et al., 2007; Andresen et al., 2011), which negatively
regulate viral gene expression and may help HTLV-1-infected cells
evade host immune-surveillance pathways as a prerequisite for viral
persistence and the development of malignant disease after many
years (Bartoe et al., 2000; Silverman et al., 2004). The antisense
protein, HBZ, interacts with the kinase-inducible exchange (KIX) and
histone acetyltransferase (HAT) domains of the transcriptional coacti-
vators, p300/CBP, and inhibits Tax-dependent transactivation from
the HTLV-1 promoter by interfering with Tax-p300/CBP binding
(Wurm et al., 2012; Clerc et al., 2008). Lemasson et al. (2007) have
also shown that HBZ directly interacts with CREB/ATF-1 transcription
factors and prevents their recruitment into Tax-CREB nucleoprotein
complexes on the viral promoter. The p30II protein (also known as
Tax-Open Reading Frame II, or Tof-II) is comprised of 241 amino acid
residues and contains arginine- and serine/threonine-rich regions
which share sequence similarities with POU-family homeodomain
transcription factors, Oct-1/2 and Pit-1, and is translated from an
alternative doubly-spliced pX mRNA (Johnson et al., 2001; Koralnik
et al., 1993; Nicot et al., 2005; Bai and Nicot, 2012; Bai et al., 2010;
Anupam et al., 2013). p30II contains three nuclear localization
signals: NLS1 (residues 66–73), NLS2 (residues 91–98), and NLS3
(residues 200–220) and two putative nucleolar localization/reten-
tion signals: NoLS1 (residues 73–78) and NoLS2 (residues 91–98)
(Koralnik et al., 1993; Nicot et al., 2005; Bai et al., 2010; Anupam
et al., 2013; Ghorbel et al., 2006), as well as a functional transcrip-
tional activation domain, spanning amino acid residues 62–220
which was characterized using Gal4 (DBD)-p30II fusion/UAS trans-
activation experiments (Zhang et al., 2000, 2001). The p30II protein
suppresses the expression of HTLV-1 antigens through distinct
transcriptional and posttranscriptional mechanisms. Zhang et al.
(2001) have demonstrated p30II binds to the KIX domain of p300/
CBP and inhibits Tax-dependent transactivation from the viral
promoter through competitive interactions with p300/CBP. The
ability of p30II to interfere with Tax-dependent transactivation
was dependent upon a single lysine residue at position 106
(K106) within the p30II protein and also required p300 HAT activity
(Michael et al., 2006). By contrast, Nicot et al. (2004) and Younis
et al. (2004) have shown that p30II inhibits HTLV-1 gene expression
by sequestering tax/rex mRNAs within nucleoli, thereby preventing
their nuclear export. The related p28II protein of HTLV-2 similarly
inhibits the nuclear export of tax/rex transcripts (Younis et al., 2004,
2006). Although the mechanism(s) by which p30II posttranscrip-
tionally regulates viral and cellular gene expression remains to be
fully elucidated (Nicot et al., 2004; Younis et al., 2004, 2006; Taylor
et al., 2009), Younis et al. (2006) have demonstrated that p30II is
recruited to Tax-containing transcription complexes on the HTLV-1
promoter and travels together with the RNA Pol II elongation complex
until it reaches a downstream target mRNA structural element.
The p13II protein, which corresponds to amino acids 155–241 of the
carboxyl-terminus of p30II, in its ubiquitinated form, has also been
shown to negatively regulate HTLV-1 gene expression by inhibiting
the ability of Tax to bind to the transcriptional coactivators p300/CBP
(Andresen et al., 2011).
In addition to its role in maintaining viral latency, we have
demonstrated that p30II cooperates with c-MYC and augments
c-MYC-dependent transcriptional and oncogenic functions through
interactions with the MYST-family acetyltransferase, TIP60, on
c-MYC-responsive gene promoters (Awasthi et al., 2005). Acute and
lymphoma-stage ATLL patient isolates frequently over-express c-MYC,
Fig. 1. HTLV-1 p30II-GFP transactivates c-MYC-responsive E-box enhancer elements within the human cyclin D2 promoter and induces Cyclin D2 expression. (A) 293A HEK
cells were transfected with increasing amounts (1.0, 2.0 μg) of CMV-HTLV-1 p30II-GFP or a pcDNA3.1-GFP control. Expression of p30II-GFP and GFP was detected by direct
ﬂuorescence-microscopy (top panels) and immunoblotting. The subcellular distributions of HTLV-1 p30II-GFP and GFP were determined by direct ﬂuorescence-microscopy.
Scale bars in the micrographs represent 100 μm. (B) Cells were co-transfected with a human cyclin D2 promoter-luciferase reporter plasmid (0.5 μg) and increasing amounts
(1.0, 2.0 μg) of CMV-HTLV-1 p30II-GFP or pcDNA3.1-GFP. (C) The cells were co-transfected as in B with a mutant cyclin D2MUT promoter-luciferase construct which lacks
conserved E-box elements in the presence of increasing CMV-HTLV-1 p30II-GFP or pcDNA3.1-GFP. (D) Cells were co-transfected with a human cyclin D2 promoter-luciferase
reporter plasmid and CMV-HTLV-1 p30II-GFP in the presence of increasing amounts of CMV-wildtype TIP60 or CMV-TIP60Q377E/G380E (1.0, 3.0 μg) (Ikura et al., 2000). (E) 293A
HEK cells were co-transfected with a cyclin D2 promoter-luciferase reporter plasmid and CMV-HTLV-1 p30II-GFP. The cells were also repeatedly transfected with an siRNA
targeted against tip60 (siRNA-tip60) or a non-speciﬁc RNA (nsRNA) control. The HTLV-1 p30II-GFP and GFP proteins were visualized by direct-ﬂuorescence microscopy (upper
right panels). The inhibition of endogenous TIP60 protein expression by the transfected siRNA-tip60 was demonstrated by immunoblotting (lower panels). Actin is shown as a
control for equivalent protein loading. A tk-renilla luciferase construct was co-transfected as a control for transfection efﬁciencies (not shown) and dual-luciferase
measurements were performed. The reported activities were normalized for equivalent renilla-luciferase activities. All luciferase assays were performed in duplicate (n¼2)
or triplicate (n¼3) and results from representative experiments are shown. The Students t-distributions (alpha¼0.05) for luciferase assay results were B: 49,001.95; C:
10,293.99; D: 15,534.79; and E: 3,892.06. (F) The expression of the FLAG-tagged TIP60wildtype and TIP60Q377E/G380E mutant proteins in HTLV-1 p30II-GFP-expressing cells was
detected by immunoﬂuorescence-microscopy using an anti-FLAG monoclonal antibody and quantiﬁed using Zeiss Axiovision 4.8 software to measure relative ﬂuorescence
intensities within individual selected cells. (G) Graphical representation of experimental results in F. Five individual cells were analyzed for each data point. The Student’s t-
distribution (alpha¼0.05) is 324.03. (H) The cellular acetyltransferases TIP60 and p300 are present in HTLV-1 p30II/c-MYC transcription complexes recruited to the
endogenous cyclin D2 promoter in HTLV-1-transformed T-lymphocytes. Chromatin-immunoprecipitations were carried out on HTLV-1-transformed HuT-102 lymphocytes
using antibodies against HTLV-1 p30II (peptide B; Koralnik et al., 1993), p300, c-MYC, and TIP60 as in Awasthi et al. (2005). Non-speciﬁc rabbit IgG was included as a control.
The precipitated oligonucleosomal DNA fragments were detected by PCR ampliﬁcation using the prm primer pair; the utr primers were used as a negative control (top
panels). Dual-ChIPs (lower panels) were performed by re-immunoprecipitating nucleoprotein complexes using individual antibodies against HTLV-1 p30II, p300, c-MYC,
TIP60, or non-speciﬁc IgG as described in Vakoc et al. (2005). The re-precipitated DNA fragments were detected by PCR using the prm primers.
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as a result of 8q24 chromosomal translocations and/or c-myc locus
gene ampliﬁcation, associated with an aggressive disease phenotype
and poor clinical outcomes (Awasthi et al., 2005; Mengle-Gaw and
Rabbitts, 1987; Okumura et al., 2012; Koizumi et al., 1989; Saggioro
et al., 1999; Hall et al., 1998; Miyazaki et al., 1996; Duyao et al., 1992).
The viral Tax protein transactivates NF-kappaB elements within the
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c-myc promoter (Duyao et al., 1992). However, Gabet et al. (2003) have
shown that Tax represses c-MYC-dependent transactivation from the
hTERT gene promoter, and Semmes et al. (1996) have also demon-
strated Tax inhibits c-MYC-dependent transcription and anchorage-
independent cell growth. Interestingly, tumors in tax transgenic mice
exhibit high levels of apoptosis associated with increased oncogene
expression, including c-MYC (Saggioro et al., 1999; Hall et al., 1998).
Thus, the cooperation between p30II and c-MYC may provide a
mechanism whereby the viral pX proteins (p30II, Tax, and/or HBZ)
coordinately regulate oncogene-activation, while inhibiting c-MYC-
induced apoptosis, to promote proviral replication and the prolifera-
tion of HTLV-1-infected T-cells.
The c-MYC oncoprotein is acetylated on multiple lysine resi-
dues by the transcriptional cofactors/acetyltransferases, p300/CBP,
PCAF/GCN5, and TIP60 (Faiola et al., 2005; Zhang et al., 2005;
Vervoorts et al., 2003; Patel et al., 2004; Vervoorts et al., 2006;
Mao et al., 2011). Faiola et al. (2005) have demonstrated that p300-
mediated lysine-acetylation of c-MYC is associated with increased
turnover and degradation of the c-MYC protein. This is in contrast
to the role of acetylation by PCAF/GCN5 and TIP60, which has been
shown to stabilize and signiﬁcantly increase the half-life of c-MYC
(Patel et al., 2004). Conversely, the Max protein, another basic
domain/helix-loop-helix/leucine zipper (bHLHZip)-family tran-
scription factor that regulates c-MYC functions, is acetylated on
lysine residues K57, K144, and K145 which is important for its
nuclear localization in mammalian cells (Faiola et al., 2007). It is
important to note that, as many of the acetylation sites within
c-MYC have been identiﬁed through in vitro biochemical studies,
the role of site-speciﬁc acetylation in c-MYC biological functions
remains to be fully determined.
The present study provides new insight into the mechanism(s)
of cooperation between p30II and c-MYC, and demonstrates that
p30II induces acetylation of the c-MYC oncoprotein which is required
for oncogenic foci-formation by p30II/c-MYC (Awasthi et al., 2005).
These ﬁndings allude to a possible role for c-myc oncogene-activation
and its cooperation with retroviral accessory proteins during proviral
replication and HTLV-1-associated T-cell leukemogenesis.
Results
Transactivation of the human cyclin D2 promoter and induction
of endogenous Cyclin D2 by HTLV-1 p30II-GFP
To determine whether an HTLV-1 p30II-GFP fusion induces expres-
sion of the endogenous Cyclin D2 protein, we cotransfected 293A
HEK cells with increasing amounts of the CMV-HTLV-1 p30II-GFP
(Nicot et al., 2004) or pcDNA3.1-GFP expression constructs.
Fig. 1. (continued)
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The relative expression of p30II-GFP and GFP was determined by
immunoblotting (Fig. 1A). As shown in Fig. 1A, higher levels of
cyclin D2 were observed to coincide with increasing amounts of
HTLV-1 p30II-GFP, relative to the GFP control. The subcellular
distribution of p30II-GFP was predominantly nuclear/nucleoplas-
mic, whereas GFP exhibited a whole-cell ﬂuorescence pattern
(Fig. 1A, right panels). We have previously demonstrated that the
HTLV-1 p30II (HA-tagged) protein interacts with the c-MYC onco-
protein and transactivates c-MYC-responsive E-box enhancer ele-
ments within the human cyclin D2 promoter, dependent upon
recruitment of the MYST-family acetyltransferase TIP60 (Awasthi
et al., 2005). Therefore, we next tested whether the p30II-GFP fusion
similarly modulates c-MYC-dependent transactivation. Results in
Fig. 1B demonstrate that increasing amounts of the CMV-HTLV-1
p30II-GFP expression construct transcriptionally activate a human
cyclin D2 promoter-luciferase reporter gene, as compared to the
pcDNA3.1-GFP control. The ability of p30II-GFP to transactivate
the cyclin D2 promoter was dependent upon the conserved
c-MYC-responsive E-box enhancer elements, as a mutant cyclin
D2MUT promoter-luciferase reporter lacking the E-boxes (Vervoorts
et al., 2003) was not transactivated by increasing p30II-GFP (Fig. 1C).
Consistent with our earlier ﬁndings that p30II stabilizes the
recruitment of the transcriptional cofactor/acetyltransferase
TIP60 to p30II/c-MYC nuclear complexes (Awasthi et al., 2005),
over-expression of wildtype TIP60 resulted in signiﬁcantly higher
transactivation of the cyclin D2 promoter by p30II-GFP (Fig. 1D). A
dominant-negative TIP60Q377E/G380E mutant, defective for acetyltrans-
ferase activity (Ikura et al., 2000), inhibited p30II-GFP-mediated
transactivation (Fig. 1D). We next tested the effects of inhibiting
TIP60 expression using a small-interfering RNA targeted against tip60
transcripts (siRNA-tip60) upon p30II-GFP-dependent transactivation
from the cyclin D2 promoter. A non-speciﬁc RNA (nsRNA) was
included as a negative control. Results in Fig. 1E demonstrate that
increasing amounts of transfected siRNA-tip60 inhibited p30II-GFP-
dependent transcriptional activation, compared to the nsRNA. The
inhibition of endogenous TIP60 protein expression by siRNA-tip60
was veriﬁed by immunoblotting (Fig. 1E, bottom right). The p30II-GFP
and GFP proteins were visualized by direct-ﬂuorescence microscopy
(Fig. 1E, upper right panels). These results collectively agree with our
previous observations in Awasthi et al. (2005) and further demon-
strate that the p30II-GFP fusion behaves in a similar transcriptional
manner as the p30II (HA-tagged) protein. To rule out the possibility
that p30II-GFP might inﬂuence expression of the FLAG-tagged
TIP60wildtype or TIP60Q377E/G380E mutant proteins in co-transfected
Fig. 2. The acetylation-defective Lys-Arg c-MYC mutants, K323R/K417R and R5, are impaired for oncogenic cellular transformation by HTLV-1 p30II-GFP/c-MYC. (A) c-myc /
 HO15.19 Fibroblasts were co-transfected with CβF-wildtype c-MYC and pcDNA3.1-GFP or CMV-HTLV-1 p30II-GFP. The transfected cultures were monitored microscopically
over a two week period and foci-formation/cellular transformation was quantiﬁed by direct counting. Transformed colonies were stained with methylene blue for
visualization. (B) An enlarged ﬁeld with multiple foci is shown in the top left panel. Expression of HTLV-1 p30II-GFP in transformed colonies was visualized by direct
ﬂuorescence-microscopy. The c-myc / HO15.19 cells exhibit a senescent morphology compared to their parental rodent TGR-1 ﬁbroblasts. (C) c-myc / HO15.19 Fibroblasts
were co-transfected with CMV-HTLV-1 p30II-GFP or pcDNA3.1-GFP and CβF-wildtype c-MYC or the Lys-Arg c-MYC mutants, K323R/K417R or R5 (Faiola et al., 2005; Patel
et al., 2004). Foci-formation was quantiﬁed by direct counting as described in A. Error bars represent standard deviations. The Student's t-distribution (alpha¼0.05) is 1.014.
(D) Effects of various dominant-negative acetyltransferase mutants upon foci-formation/cellular transformation by HTLV-1 p30II (HA)/c-MYC were determined by co-
transfecting immortalized human wrn / WS AG11395 ﬁbroblasts with CMV-HTLV-1 p30II (HA)/CβF-c-MYC and increasing amounts (1.0, 2.0 μg) of CMV-TIP60Q377E/G380E,
CMV-PCAFΔHAT, or CMV-p300ΔE1A. The Student's t-distribution (alpha¼0.05) is 1.903.
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cells, we performed immunoﬂuorescence-microscopy using an
anti-FLAG antibody, and then quantiﬁed the relative ﬂuorescence
intensities of the TIP60-FLAG proteins within individual cells with
Zeiss Axiovision 4.8 software. As shown in Fig. 1F and G, the TIP60-
FLAG proteins were comparably expressed in co-transfected 293A
cells containing either CMV-HTLV-1 p30II-GFP or the CβS empty
vector.
Recruitment of the acetyltransferases TIP60 and p300 to p30II/c-MYC
transcription complexes in HTLV-1-transformed T-cells
Using chromatin-immunoprecipitations (ChIPs), we have shown
that the retroviral p30II accessory protein is recruited, together with
c-MYC and its associated transcriptional cofactors TIP60, p300, and
TRRAP/p434, to E-box enhancer elements within the cyclin D2
Fig. 3. The acetylation-impaired Lys-Arg c-MYC mutant proteins, K323R/K417R and R5, colocalize with nuclear HTLV-1 p30II-GFP. (A) The subcellular distribution of HTLV-1
p30II-GFP and wildtype c-MYC, or the acetylation-defective c-MYC K323R/417R and R5 mutant proteins, was observed in cotransfected HeLa cells and (B) c-myc / HO15.19
ﬁbroblasts by immunoﬂuorescence-microscopy. A pcDNA3.1-GFP expression construct was included as a negative control. The graphs at right were generated using Zeiss
AxioVision 4.8 software and represent a heat-map of colocalization for the indicated areas (dotted lines). DIC phase-contrast images with DAPI nuclear-staining are shown
for reference. The scale bars represent 10 μM. UT, untransfected cells.
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promoter in HTLV-1-transformed T-lymphocytes (Awasthi et al.,
2005). Now, extending these ﬁndings, we have used dual-ChIPs
(Vakoc et al., 2005) to determine if p30II, c-MYC, TIP60, and p300 are
present within the same nucleoprotein complex assembled on E-box
elements in the cyclin D2 promoter in HTLV-1-transformed HuT-102
T-cells. In the dual-ChIP assay, cross-linked bound oligonucleosomal
protein complexes are initially immunoprecipitated using individual
antibodies and Protein A-agarose in a standard ChIP. However,
the ChIP-ed complexes are then re-immunoprecipitated from each
sample using a second series of antibodies to detect factors that are
Fig. 4. HTLV-1 p30II induces Lys-acetylation of the c-MYC oncoprotein. (A) The HTLV-1 p30II-GFP was immunoprecipitated with FLAG-tagged wildtype c-MYC, c-MYC K323R/
K417R and R5 mutant proteins using a monoclonal anti-FLAG M2 antibody (Sigma) and Protein-G agarose (Invitrogen). 293T HEK cells were co-transfected with CβF-
wildtype c-MYC or the Lys-Arg mutants K323R/K417R or R5, and CMV-HTLV-1 p30II-GFP or a pcDNA3.1-GFP control. Expression of the over-expressed wildtype and mutant
c-MYC proteins and Actin was detected by immunoblotting. The bound immunoprecipitated HTLV-1 p30II-GFP was detected using a rabbit polyclonal anti-GFP antibody
(Sigma). Non-speciﬁc bands are indicated, ns. (B) Diagram of the c-MYC oncoprotein (MBI/MBII, MYC boxes I and II; A, acidic region; B, basic region; HLH, helix-loop-helix
motif; LZ, leucine zipper motif; TAD, transcriptional activation domain; NLS, nuclear localization sequence). Speciﬁc Lys residues acetylated by p300/CBP (solid triangles),
PCAF/hGCN5 and TIP60 (open circles) acetyltransferases are indicated (Faiola et al., 2005; Patel et al., 2004; Veroorts et al., 2003; Zhang et al., 2005). (C) The HTLV-1 p30II-
GFP induces Lys-acetylation of c-MYC. 293 HEK cells were cotransfected with CβF-c-MYC and increasing amounts of CMV-HTLV-1 p30II-GFP or an empty vector. The
expression of HTLV-1 p30II-GFP and c-MYC was detected by immunoblotting. The over-expressed FLAG-tagged c-MYC protein was immunoprecipitated using an anti-FLAG
M2 antibody. Actin is shown as a control for equivalent protein loading. The Lys-acetylated c-MYC protein was immunoprecipitated using an anti-Acetyl-Lysine antibody
(Millipore) and detected by immunoblotting as described in Patel et al. (2004). (D) The c-MYC oncoprotein is acetylated in HTLV-1-transformed HuT-102 and MJG11
T-lymphocytes. Uninfected Jurkat E6.1 T-lymphocytes are shown as a negative control. Input levels of endogenous p30II, c-MYC, and Actin were determined by
immunoblotting. Immunoprecipitations were performed using an anti-Acetyl-Lysine antibody (left lanes) or monoclonal anti-GFP antibody control (right lanes). Lysine-
acetylated c-MYC was detected by immunoblotting. A non-speciﬁc band, ns, is indicated. (E) Effects of the HDAC-inhibitor, trichostatin A (TSA), upon HTLV-1 p30II
transactivation were determined by co-transfecting 293A cells with a cyclin D2 promoter-luciferase reporter plasmid (0.5 μg) and CMV-HTLV-1 p30II-GFP or pcDNA3.1-GFP in
the presence of increasing TSA (200, 400 ng/ml). The Student's t-distribution (alpha¼0.05) is 8153.91. The expression of HTLV-1 p30II-GFP and GFP was detected by direct
ﬂuorescence-microscopy (not shown).
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present together in a single nucleoprotein complex (Vakoc et al.,
2005). As shown in Fig. 1H, we now provide the ﬁrst evidence that
p30II (immunoprecipitated using the rabbit polyclonal anti-HTLV-1
p30II, Peptide B, antibody – kindly provided by Dr. G. Franchini, NCI/
NIH; Koralnik et al., 1993) is recruited with c-MYC, TIP60, and
p300 to E-boxes in the cyclin D2 promoter in HTLV-1-transformed
T-lymphocytes. Non-speciﬁc rabbit IgG was included as a negative
ChIP control (Fig. 1H). Intriguingly, in complementary dual-ChIPs,
TIP60 and p300 seemed to only weakly associate, which suggests
these individual factors may be separated in the p30II/c-MYC com-
plex (Fig. 1H).
Acetylation-defective Lys-Arg c-MYC substitution mutants are
impaired for oncogenic cellular transformation by p30II/c-MYC
To determine if lysine-acetylation of the c-MYC oncoprotein is
required for its cooperation with p30II (Awasthi et al., 2005), we
performed in vitro cell transformation/foci-formation assays using
c-myc / HO15.19 rodent ﬁbroblasts which are knocked out for the
c-myc gene (Albihn et al., 2006; Mateyak et al., 1997). The cultures
were cotransfected with CMV-HTLV-1 p30II-GFP or a pcDNA3.1-GFP
control, and either CβF-wildtype c-MYC or expression constructs for
the acetylation-impaired Lys-Arg mutants, c-MYC K323R/K417R
(Patel et al., 2004) or c-MYC R5 (Faiola et al., 2005). Colony
formation –indicative of a loss of cellular contact-inhibition asso-
ciated with oncogenic transformation (Awasthi et al., 2005), was
observed following 2 weeks and the transformed foci were stained
with methylene blue for enhanced visualization (Fig. 2A and B). The
c-myc / HO15.19 ﬁbroblasts grow as a monolayer and typically
exhibit a senescence-like cellular morphology and reduced prolif-
erative rate, as compared to the parental TGR-1 rat ﬁbroblasts
which are more spindle-shaped (Fig. 2B, right panels). The co-
expression of wildtype c-MYC together with the GFP control did not
result in signiﬁcant foci-formation (approximately 6 colonies for
c-MYC/GFP, versus 7 colonies for untransfected cells; Fig. 2A and C).
In agreement with our previous data in Awasthi et al. (2005),
the xc-MYC oncoprotein cooperated with HTLV-1 p30II to induce
oncogenic cellular transformation and resulted in approximately 42
colonies (Fig. 2A–C). The expression of p30II-GFP within trans-
formed colonies was visualized by direct ﬂuorescence-microscopy
Fig. 5. The HTLV-1 p30II protein inhibits c-MYC-dependent apoptosis induced by genotoxic stress. (A) Cellular apoptosis was quantiﬁed in co-transfected c-myc / HO15.19
ﬁbroblasts expressing c-MYC or the acetylation-defective Lys-Arg c-MYC mutants, and HTLV-1 p30II. The cells were transfected with a CβS vector control, CMV-HTLV-1 p30II
(HA), or CβF-c-MYC alone (1.5 μg each), or in combination with wildtype c-MYC or the K323R/K417R and R5 mutants. Certain cultures were treated with C2-ceramide (50 μM)
as a positive control for apoptosis. Programmed cell-death was measured by staining the co-transfected cells with Annexin-V-FITC/PI (BD-Pharmingen) and performing ﬂow-
cytometry. (B) To visualize apoptosis in adherent cultures by microscopy, c-myc / HO15.19 ﬁbroblasts were co-transfected with CβF-c-MYC and CMV-HTLV-1 p30II (HA) or a
CβS vector. The c-MYC/HTLV-1 p30II (HA)-induced colonies were also analyzed to determine the level of apoptosis in transformed foci. C2-ceramide-treated cells were
included as a positive control for apoptosis (bottom). The transfected cells were stained with Annexin-V-FITC (BD-Pharmingen) and apoptosis was detected by direct
ﬂuorescence-microscopy. Expression of the HTLV-1 p30II (HA) protein was detected using a monoclonal anti-HA antibody (CA5, Roche Molecular Biochemicals). (C) c-myc /
HO15.19 Fibroblasts were co-transfected with CβF-wildtype c-MYC (or the acetylation-defective c-MYC mutant, K323R/K417R) and CMV-HTLV-1 p30II (HA) or a CβS control.
Apoptosis and cell-cycle progression were measured by labeling cultures with BrdU for 12 h and subsequently staining permeablized/ﬁxed cells with an anti-BrdU-FITC-
conjugated antibody and 7-AAD (BD-Pharmingen) and performing ﬂow-cytometric analyses. Cell populations with diploid (2N, 4N) or polyploid (4N, 8N, 16N) DNA content
are indicated. (D) To visualize the effects of HTLV-1 p30II (HA) upon apoptosis induced by c-MYC or Lys-Arg c-MYC mutants in the presence of genotoxic stress
(i.e., prolonged exposure to BrdU), c-myc / HO15.19 ﬁbroblasts were co-transfected with various combinations of CβS vector, CMV-HTLV-1 p30II (HA), CβF-wildtype c-MYC
or acetylation-defective Lys-Arg c-MYC mutants and exposed to BrdU for 12 h. Staurosporine (1 μM) and C2-ceramide (60 μM)-treated cultures were included as positive
controls for apoptosis. The transfected cells were stained using Annexin-V-FITC and analyzed by direct ﬂuorescence-microscopy. (E) The Apoptotic Index (number of Annexin
V-FITC-positive cells/Field) was obtained by counting and averaging the number of Annexin V-FITC-positive cells in three separate microscopic ﬁelds. The graph shows
average data from duplicate experiments and error bars representing standard deviations are provided. A representative experiment is shown in (F). The average percentages
of Annexin-V-FITC-positive cells per ﬁeld were determined by counting three microscopic ﬁelds for each sample. Standard deviations are represented by the error bars. The
Student’s t-distribution (alpha¼0.05) is 1.700. Representative micrographs depicting the Annexin V-FITC-staining (green) and DIC phase contrast in merged images are
shown at right.(For interpretation of the references to color in this ﬁgure legend, the reader is referred to the web version of this article.)
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(Fig. 2B). Importantly, the acetylation-impaired Lys-Arg c-MYC
mutants, K323/K417R and R5, were defective for oncogenic trans-
formation and cooperation with p30II (Fig. 2C), suggesting that
acetylation of the c-MYC oncoprotein might be required for its
molecular interactions with p30II (Awasthi et al., 2005; Faiola et al.,
2005; Vervoorts et al., 2003; Patel et al., 2004). Consistent with
these ﬁndings, the co-expression of increasing amounts of various
dominant-negative acetyltransferase mutants: TIP60Q377E/G380E,
PCAFΔHAT, and p300ΔE1A (Moser et al., 2000; Ikura et al., 2000;
Chakravarti et al., 1999; Yang et al., 1996), inhibited HTLV-1 p30II/c-
MYC-induced oncogenic cellular transformation in vitro in the
wrn / WS AG11395 ﬁbroblast cell-line, which was the line used
to originally demonstrate the oncogenic cooperation between p30II
and c-MYC (Fig. 2D; Awasthi et al., 2005). We recognize, however,
that these dominant-negative coactivator mutants are likely to have
a pleiotropic negative impact upon cellular transcription as well as
cell proliferation in general.
The HTLV-1 p30II protein interacts with the Lys-Arg c-MYC mutants
and induces acetylation of the c-MYC oncoprotein
We next sought to determine if the impairment in oncogenic
transformation by p30II and the acetylation-defective Lys-Arg c-MYC
mutants, K323R/K417R and R5, is due to reduced interactions between
p30II and c-MYC (Awasthi et al., 2005). Both of the Lys-Arg c-MYC
mutant proteins colocalized with HTLV-1 p30II-GFP, similar to the
wildtype c-MYC, in nuclei of cotransfected c-myc–/–HO15.19 ﬁbroblasts
or HeLa cells (Fig. 3A and B). The expression of HTLV-1 p30II-GFP,
GFP, and c-MYC proteins was detected by immunoﬂuorescence-
microscopy. Untransfected c-myc / HO15.19 or HeLa cells (UT) and
pcDNA3.1-GFP were included as negative controls (Fig. 3A and B). The
p30II-GFP fusion localized to the nucleus/nucleolus with a subfraction
distributed throughout the cytoplasm, whereas GFP exhibited a
whole-cell ﬂuorescence pattern (Fig. 3A and B). Further, we demon-
strated that the p30II-GFP co-immunoprecipitates with FLAG epitope-
tagged wildtype c-MYC, as well as the acetylation-defective Lys-Arg
c-MYC mutants, K323R/K417R and R5, in whole-cell extracts prepared
from cotransfected 293T HEK cells (Fig. 4A). These results suggest the
impairment in the cooperation between HTLV-1 p30II and the Lys-
Arg c-MYC mutants (Fig. 2C) is not derived from impaired molecular
interactions with p30II, but, rather, could reﬂect the defective acetyla-
tion status of the c-MYC mutant proteins (Faiola et al., 2005; Patel
et al., 2004).
A diagram of the c-MYC oncoprotein depicting its acetylation sites
is shown in Fig. 4B (Faiola et al., 2005; Vervoorts et al., 2003; Patel
et al., 2004). The p30II-GFP fusion induces lysine-acetylation of FLAG
Fig. 5. (continued)
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epitope-tagged c-MYC in cotransfected 293 HEK cells, as compared to
an empty vector control (Fig. 4C). The acetylated c-MYC protein was
immunoprecipitated using an anti-Acetyl-Lysine antibody (Millipore)
and detected by immunoblotting as described in Patel et al. (2004);
Fig. 4C. We also observed that c-MYC is acetylated in HTLV-1-
transformed T-cell-lines, HuT-102 and MJG11 (Fig. 4D). Uninfected
Jurkat lymphoblastic leukemia cells were included for comparison
(Fig. 4D). The endogenous p30II protein was detected in HTLV-1-
infected cells using the rabbit polyclonal Peptide B antibody (Koralnik
et al., 1993). The acetylated c-MYC oncoprotein was immunoprecipi-
tated using an anti-Acetyl-Lysine antibody as described; and an anti-
GFP antibody was included as a control for IP speciﬁcity (Fig. 4D,
lower panel). These ﬁndings together suggest that acetylation of the
c-MYC protein is required for its oncogenic cooperation with p30II.
Consistent with this notion, a chemical histone deacetylase (HDAC)-
inhibitor, Trichostatin A (TSA), signiﬁcantly increased the transcrip-
tional activation from a human cyclin D2 promoter-luciferase reporter
plasmid by p30II-GFP in cotransfected cells (Fig. 4E; Awasthi et al.,
2005; Bouchard et al., 2001).
HTLV-1 p30II inhibits c-MYC-dependent cellular apoptosis
in the presence of genotoxic stress
To determine if p30II and acetylation of the c-MYC protein
inﬂuence c-MYC-dependent programmed cell death, we cotransfected
c-myc / HO15.19 ﬁbroblasts with expression constructs for wildtype
c-MYC or the Lys-Arg acetylation-defective mutants, K323R/K417R
and R5, together with HTLV-1 p30II (HA) or an empty CβS vector
control. Cells were also treated with the sphingolipid C2-ceramide as a
positive control for apoptosis. Programmed cell death was detected
and quantiﬁed by staining the cotransfected cultures with Annexin-
V-FITC and propidium iodide (BD-Pharmingen) and subsequent
analysis by ﬂow cytometry. We did not observe signiﬁcant
differences in cellular apoptosis for the wildtype c-MYC or
acetylation-defective mutant proteins, relative to the control, when
expressed alone in the c-myc / HO15.19 background (Fig. 5A).
Apoptosis was also visualized by Annexin-V-FITC-staining and
immunoﬂuorescence microscopy in cotransfected c-myc /
HO15.19 cells as well as transformed foci expressing p30II (HA)/c-
MYC (Fig. 5B). Surprisingly, with prolonged 12-h labeling of the
cotransfected cells with bromodeoxyuridine (BrdU) for ﬂow cyto-
metric cell-cycle analyses, we found that c-MYC-expressing cells
exhibited signiﬁcantly more apoptosis than p30II/c-MYC-expressing
cells, which also contained polyploidy as noted in Awasthi et al.
(2005; Fig. 5C). We therefore cotransfected HO15.19 ﬁbroblasts to
express various combinations of wildtype c-MYC or the Lys-Arg
acetylation-defective mutants, K323R/K417R and R5, together with
HTLV-1 p30II(HA) or empty vector control, and subsequently treated
the cultures for 12-hr with BrdU. Then the cells were stained with
Annexin-V-FITC and apoptosis was measured by visually counting,
in triplicate, the numbers of Annexin-V-FITC-positive cells per ﬁeld
(Fig. 5D). Results shown in Fig. 5D and graphed in Fig. 5E demon-
strate that the c-MYC/empty CβS vector combination induced high
levels of apoptosis, as compared to cells expressing p30II(HA)/c-MYC
(Fig. 5D and E). The K323R/K417R and R5 acetylation-defective
mutants did not induce signiﬁcant apoptosis in the presence of
prolonged BrdU treatment (Fig. 5E; data not shown), which may
reﬂect a general functional impairment of these mutants in their
ability to promote cellular proliferation. A representative experiment
is shown in Fig. 5F which demonstrates that p30II signiﬁcantly
protects against c-MYC-dependent apoptosis in the presence of
prolonged genotoxic stress induced by BrdU-treatment. The micro-
graphs in the right panels depict the Annexin-V-FITC-staining results
in Fig. 1F.
Datta et al. (2007) have previously reported that p30II protects
primary T-cell-lines expressing the HTLV-1 proviral clone ACH.1
Fig. 5. (continued)
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Fig. 6. HTLV-1 p30II induces multinucleation in the presence of subinhibitory concentrations of etoposide. (A) HFL1 Human fetal lung ﬁbroblasts were transfected with CMV-
HTLV-1 p30II-GFP or a pcDNA3.1-GFP control and certain cultures were treated with subinhibitory concentrations (o 1 μM) of the genotoxin, etoposide. The cultures were
incubated for 96 h at 37 1C and 5% CO2 and multinucleation was quantiﬁed in the GFP-positive cells. Error bars represent standard deviations in triplicate assays. The
Student’s t-distribution (alpha¼0.05) is 0.128. (B) HFL1 Fibroblasts were transfected as in A and cultured in the absence or presence of subinhibitory levels of etoposide.
Multinucleation was visualized in HTLV-1 p30II-GFP and GFP-expressing cells by ﬂuorescence-microscopy. The cells were immunostained to detect induction of the p53
tumor suppressor; and nuclei were visualized by DAPI-staining. Actin was stained using Texas-Red (TR)-Phalloidin. The open arrows indicate multinucleation in the GFP-
positive cells. (C) Cells were transduced with a lentiviral vector expressing the HTLV-1 p30II (HA-tagged) protein, or an empty lentiviral vector, and then treated with
etoposide as described. The cultures were subsequently labeled with BrdU for 6 hrs and stained with an anti-BrdU-FITC antibody (BD Pharmingen) to detect cells in S-phase.
The p30II (HA) protein was visualized in transduced cells by immunoﬂuorescence-microscopy using an anti-HA (12CA5) monoclonal antibody (lower panels). DAPI-nuclear-
staining is shown in the merged images for comparison.
against Camptothecin-induced apoptosis, compared to cells con-
taining the ACH.30.1 mutant defective for p30II production. Similar
to Camptothecin, genomic BrdU-incorporation produces DNA-
damage (single strand breaks) and genotoxic stress and cytotoxi-
city (Ackland et al., 1988) that is countered by the HTLV-1 p30II
protein. To further test the effects of p30II in the presence of
genotoxic stress, we transfected HFL1 human fetal lung ﬁbroblasts
with CMV-HTLV-1 p30II-GFP or a pcDNA3.1-GFP control and
treated certain cultures with subinhibitory concentrations of the
chemical Topoisomerase II-inhibitor, etoposide, and subsequently
monitored them for the induction of multinucleate cells. A low,
but detectable level of multinucleation was observed in the GFP-
expressing control cells treated with the chemical inhibitor
(approximately 2%, Fig. 6A and B). Consistent with our previous
observations (Awasthi et al., 2005), p30II-GFP expression resulted
in signiﬁcantly more multinucleation in the presence of etoposide
(4 6%, Fig. 6A and B), which could possibly be attributed to
the induction of c-MYC and aberrant DNA-endoreduplication fol-
lowing p53-dependent G2/M-arrest (Awasthi et al., 2005; Datta et
al., 2007). We and others have shown that p30II induces the
accumulation of cells in the G2-phase of the cell cycle (Awasthi et
al., 2005; Datta et al., 2007). As p53 regulates the G2/M checkpoint
through the induction of regulatory factors, including 14–3–3σ and
p21Waf/Cip1 (Chan et al., 2000), we therefore examined p53 expres-
sion in p30II-GFP-expressing cells in the presence or absence of
etoposide. These studies revealed that p53 protein levels were
increased in both p30II-GFP-expressing and etoposide-treated HFL1
ﬁbroblasts (Fig. 6B). To determine whether p30II might promote c-
MYC-dependent DNA endoreduplication in etoposide-treated cells,
we next transduced HFL1 ﬁbroblasts with a lentiviral vector expres-
sing HTLV-1 p30II (HA-tagged), or an empty lentiviral vector, and
then treated the cultures with etoposide as described. The cells were
subsequently labeled with BrdU for 6 h and stained with an anti-
BrdU-FITC antibody (BD Pharmingen) to identify cells in the S-phase
of the cell cycle. The HTLV-1 p30II (HA) protein was detected
by immunoﬂuorescence-microscopy (Fig. 6C, lower panels). These
results demonstrate that p30II-expressing cells incorporated the
BrdU deoxynucleotide analog into their genome under conditions
of etoposide-treatment (Fig. 6C). We were not able to detect c-MYC-
acetylation in the etoposide-treated cells, which express low levels
of full-length c-MYC (data not shown). Conacci-Sorrell et al. (2014)
recently reported the majority of c-MYC is cleaved by the Calpain
protease into a truncated form (designated ‘MYC-nick’), containing
amino acid residues 1–298, in the presence of etoposide. This
proteolytic processing would remove lysine residues K323 and
K417 which were identiﬁed as putative targets for acetylation by
pLenti 6.2/V5-DEST vector +ETOP
pLenti-HTLV-1 p30II (HA) +ETOP
Untreated
Fig. 6. (continued)
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TIP60 (Patel et al., 2004). Therefore, the levels of acetylated full-
length c-MYC may be too low to detect using our current IP methods
in etoposide-treated cells.
Our results allude to a mechanistic model whereby p30II
induces acetylation of the c-MYC oncoprotein to augment its
transcriptional activity, and inhibits c-MYC-dependent cellular
apoptosis in the presence of genotoxic stress –which could lead
to the increased accumulation of somatic mutations and genomic
instability associated with oncogenic transformation and viral
carcinogenesis (Fig. 7; Awasthi et al., 2005). As DNA-damage-
inducing agents, such as etoposide, hydroxydaunorubicin, and
cyclophosphamide are used in the CHOP (cyclophosphamide,
hydroxydaunorubicin, oncovin, prednisolone) anticancer che-
motherapy regimen for the clinical management of ATLL, our
present ﬁndings suggest that retroviral proteins, such as p30II,
may interfere with the cytopathic killing effects of these drugs and
could promote the accumulation of somatic mutations which
could contribute to disease progression.
Discussion
We are studying how the persistently expressed latency-
maintenance factors (i.e., p30II, HBZ, p13II) of HTLV-1 inﬂuence host
cellular pathways to promote proviral replication and contribute to
disease progression during viral carcinogenesis (Nicot et al., 2005; Bai
and Nicot, 2012; Arnold et al., 2006; Awasthi et al., 2005; Li et al.,
2009; Bai et al., 2010; Anupam et al., 2013; Michael et al., 2006; Zhang
et al., 2001; Nicot et al., 2004; Younis et al., 2004, 2006; Bartoe et al.,
2000; Silverman et al., 2004; Clerc et al., 2008; Lemasson et al., 2007;
Andresen et al., 2011). Whereas the transactivator protein, Tax, is
recognized to play a pivotal role during the earliest stages of T-cell
immortalization and oncogenesis (Johnson et al., 2001; Kannian and
Green, 2010; Currer et al., 2012; Hasegawa et al., 2006; Swaims et al.,
2010; Rauch et al., 2009; Mitra-Kaushik et al., 2004; Grossman and
Ratner, 1997), other viral pX factors (p30II, p13II, and HBZ) have been
shown to negatively regulate proviral gene expression and inhibit
Tax-dependent transactivation of the HTLV-1 50 LTR (Nicot et al.,2004,
2005; Bai and Nicot, 2012; Arnold et al., 2006; Bai et al., 2010;
Anupam et al., 2013; Michael et al., 2006; Zhang et al., 2001; Younis
et al., 2004, 2006; Silverman et al., 2004; Clerc et al., 2008; Lemasson
et al., 2007; Andresen et al., 2011). These proteins help to maintain
latency by suppressing the expression of viral antigens which is
required for HTLV-1-infected T- lymphocytes to evade host immune-
surveillance pathways and establish long-term proviral persistence
(Johnson et al., 2001; Nicot et al., 2005; Edwards et al., 2011; Bai and
Nicot, 2012; Arnold et al., 2006; Li et al., 2009; Bai et al., 2010;
Anupam et al., 2013; Bartoe et al., 2000; Silverman et al., 2004). The
p30II accessory protein contains a transcriptional activation domain
between amino acid residues 62–220 and interacts with the transcrip-
tional cofactors, p300/CBP and TIP60 (Awasthi et al., 2005; Michael
et al., 2006; Zhang et al., 2000, 2001). We and others have published
microarray gene expression analyses of cellular target genes whose
expression is activated or repressed by p30II (Awasthi et al., 2005;
Taylor et al., 2009; Michael et al., 2004). In the Awasthi et al. (2005)
study, by including a dominant-negative TIP60Q377E/G380E HAT mutant
(Ikura et al., 2000), we identiﬁed several downstream target genes
transcriptionally activated by p30II whose expression is dependent
upon the TIP60 acetyltransferase. p30II differentially regulates CREB-
dependent transcription, and inhibits Tax-quaternary complex forma-
tion with CREB and p300 on 21-bp-repeat Tax-responsive elements
(TREs) through binding to the KIX domain of p300 (Michael et al.,
2006; Zhang et al., 2000, 2001). Datta et al. (2006) have also shown
that p30II inhibits DNA-binding by PU.1 and represses (Toll-like
receptor-4) TLR4 inﬂammatory signaling in macrophages. These
studies were recently extended by Fenizia et al. (2014), who demon-
strated that p30II inhibits the expression of interferon-responsive
genes following lipopolysaccharide-stimulation of TLR3 and TLR4 in
monocytes and dendritic cells, which may contribute to a permissive
cellular phenotype during early-stage infection as well as throughout
the course of persistent disease.
We have previously demonstrated that p30II interacts with
TIP60 and enhances c-MYC-dependent transcriptional activation
and oncogenic potential (Awasthi et al., 2005). However, the
molecular mechanism(s) by which p30II cooperates with c-MYC
remains to be fully elucidated. Herein, we have shown that p30II
Fig. 7. Model depicting c-MYC-acetylation on multiple lysines by cellular acetyltransferases and its role in retroviral carcinogenesis. The HTLV-1 p30II accessory protein
interacts with TIP60 and p300/CBP, induces acetylation of the c-MYC oncoprotein, and augments c-MYC transcriptional activity and oncogenic potential. p30II also inhibits
c-MYC-dependent apoptosis induced by genotoxic stress, which could promote continuous DNA-replication and the acquisition of genetic lesions that support oncogenic
transformation.
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is recruited to c-MYC/TIP60/p300 transcriptional complexes on
E-box enhancer elements within the endogenous cyclin D2 promoter
in HTLV-1-transformed HuT-102 T-lymphocytes using dual-ChIPs
(Fig. 1H). p30II induces acetylation of the c-MYC oncoprotein in
transfected 293 cells (Fig. 4C); and c-MYC is also strongly acetylated
in the HTLV-1-infected T-cell-lines HuT-102 and MJG11 (Fig. 4D). In
the Awasthi et al. (2005) study, we demonstrated that amino acid
residues 99–154 of p30II interact with the TIP60 acetyltransferase,
which functions as a transcriptional cofactor and has been shown to
acetylate the c-MYC protein (Patel et al., 2004; Frank et al., 2003).
The speciﬁc sites of TIP60-mediated acetylation within c-MYC are
yet to be identiﬁed (Patel et al., 2004). Furthermore, we found that
the acetylation-defective Lys-Arg substitution mutants of c-MYC
(R5 and K323R/K417R) are impaired for oncogenic cellular transfor-
mation/foci formation with p30II in cotransfected c-myc / HO15.19
ﬁbroblasts (Fig. 2AC).
We did not observe discernable differences in cellular apoptosis
induced by wildtype c-MYC or the acetylation-defective c-MYC
mutants K323/R/K417R or R5 in the presence of p30II in cotrans-
fected c-myc / HO15.19 ﬁbroblasts (Fig. 5A and B). As Datta et al.
(2007) have reported that p30II expression inhibits apoptosis
induced by genotoxic stress in Camptothecin-treated primary
T-lymphocytes transduced with an HTLV-1 ACH proviral clone, we
next tested whether c-MYC-acetylation plays a role in the ability of
p30II to protect against cell-death induced by DNA-damage-inducing
agents. Interestingly, p30II signiﬁcantly inhibited c-MYC-dependent
apoptosis caused by prolonged exposure to BrdU, which induces
single-strand DNA breaks (Fig. 5C–F; Ackland et al., 1988). Neither of
the acetylation-defective c-MYC mutants resulted in increased apop-
tosis in BrdU-treated cells (Fig. 5C–F). This could be attributed to an
inability of these mutants to restore normal cell-cycle functions and
genomic replication in transfected c-myc / HO15.19 ﬁbroblasts, as
compared to wildtype c-MYC.We also observed that p30II results in an
increased number of multinucleate cells in the presence of the
genotoxic chemical, etoposide (Fig. 6A and B). These ﬁndings collec-
tively agree with our previous results (Awasthi et al., 2005) and those
in Datta et al. (2007), as well as the report by Baydoun et al. (2011)
that p30II promotes error-prone nonhomologous-end-joining DNA-
repair.
Doueiri et al. (2012) have reported a list of proteins detected in the
interactomes of S-tagged HTLV-1 p30II and related HTLV-2 p28II
proteins, based upon S-tag afﬁnity puriﬁcation and mass spectro-
metric/proteomic analyses. Noticeably, however, these studies failed to
detect interactions between p30II and TIP60, c-MYC, or other known
p30II-binding partners including p300/CBP, CREB, PU.1, and large
ribosomal subunit protein L18a (Awasthi et al., 2005; Michael et al.,
2006; Zhang et al., 2000, 2001; Ghorbel et al., 2006; Datta et al., 2006;
Doueiri et al., 2012). Using the I-TASSER computational protein-folding
and structure prediction algorithm (University of Michigan, 〈http://
zhanglab.ccmb.med.umich.edu/I-TASSER/〉), we determined that the
TIP60-binding domain (aa residues 99–154; Awasthi et al., 2005) of
the S-tagged p30II protein is predicted to be misfolded and likely
inaccessible, compared to the wildtype p30II protein structure
(Supplementary Fig. S1). Thus, albeit intriguing, the signiﬁcance of
the interacting factors identiﬁed through this proteomic screen
remains to be determined until the biological functionality (e.g.,
inhibition of Tax-dependent transactivation, cooperation with onco-
proteins, or nuclear sequestration of tax/rex mRNA) of the S-tagged
p30II protein has been demonstrated (Doueiri et al., 2012).
The c-MYC oncoprotein is frequently overexpressed in acute
and lymphoma-stage ATLL clinical isolates, as a result of 8q24
chromosomal translocations and/or c-myc locus gene ampliﬁca-
tion (Awasthi et al., 2005; Mengle-Gaw and Rabbitts, 1987;
Okumura et al., 2012; Koizumi et al., 1989; Saggioro et al., 1999;
Hall et al., 1998; Miyazaki et al., 1996; Duyao et al., 1992). c-MYC
regulates cellular proliferation and differentiation (Link et al.,
2012; Takahashi et al., 2007; Souﬁ et al., 2012), and has been
shown to function as a non-linear ampliﬁer of transcriptionally
active genes in lymphocytes and embryonic stem cells (Nie et al.,
2012). While it is assumed the primary purpose of p30II's coopera-
tion with c-MYC is to promote proviral replication in HTLV-1-
infected cells (Awasthi et al., 2005), these molecular interactions
could contribute to disease progression associated with c-MYC
deregulation in acute T-cell leukemia or lymphoma-stage ATLL
(Mengle-Gaw and Rabbitts, 1987; Okumura et al., 2012; Koizumi
et al., 1989; Saggioro et al., 1999; Hall et al., 1998; Miyazaki et al.,
1996; Duyao et al., 1992). Our ﬁndings further suggest that p30II
(and other HTLV-1 proteins) may interfere with the cytopathic
effects of CHOP-regimen DNA-damage-inducing chemotherapy
drugs, such as etoposide, hydroxydaunorubicin, or cyclophospha-
mide, used in the clinical management of ATLL and could promote
the accumulation of somatic mutations which may lead to the
development of advanced acute- or lymphoma-stage disease.
Therefore, it is intriguing to speculate that it may become possible
to sensitize ATLL tumor lymphocytes to oncogene-induced apop-
tosis in the presence of DNA-damage-inducing chemotherapy
drugs by targeting the latency-maintenance factor p30II and/or
its interactions with host cellular components.
Materials and methods
Cell culture and transfections
293 HEK cells (ATCC, CRL-1573), 293A (Quantum Biotechnology)
and 293T/17 (ATCC, CRL-11268) cells were seeded at 2105 cells/
well in six-well plates or 60 mm2 tissue-culture dishes (Nalge) and
cultured in ATCC 46-X medium or Eagle's minimum essential
medium (EMEM; ATCC) supplemented with sodium bicarbonate
(Invitrogen), 10% fetal bovine serum (FBS; Atlanta Biologicals, Bio-
west), 100 U/ml penicillin, and 100 μg/ml streptomycin sulfate
(Invitrogen) at 37 1C under 5% CO2. For certain experiments, 293A
HEK cells were cultured in the presence of 2% FBS. Immortalized
human wrn / WS ﬁbroblasts (AG11395) (Moser et al., 2000),
parental TGR1 and c-myc / HO15.19 rat ﬁbroblasts (Albihn et al.,
2006; Mateyak et al., 1997), and HeLa cells (ATCC, CCL-2) were
grown in Dulbecco's modiﬁed Eagle's medium (DMEM; ATCC)
supplemented as described. The HFL1 human fetal lung ﬁbroblast
cell-line (ATCC, CCL-153) was cultured in F-12K medium. HTLV-1-
transformed T-cell lines, HuT-102 (ATCC, TIB-162) and MJG11 (ATCC,
CRL-8294), and Jurkat E6.1 T-lymphocytes (ATCC, TIB-152) were
cultured in RPMI 1640 medium (ATCC) supplemented with 20% FBS,
100 U/ml penicillin, 100 μg/ml streptomycin sulfate (Invitrogen),
and 20 μg/ml gentamicin sulfate (SIGMA-Aldrich).
The N3-CMV-HTLV-1 p30II-GFP and pMH-CMV-HTLV-1 p30II
(HA-tagged) expression constructs (Nicot et al., 2004), human cyclin
D2 promoter-luciferase and cyclin D2MUT-luciferase reporter plas-
mids (Vervoorts et al., 2003; Bouchard et al., 2001), pOZ-CMV-TIP60
and pOZ-CMV-TIP60Q377E/G380E (Ikura et al., 2000), pSI-CMV-
p300ΔE1A and pCX-CMV-PCAFΔHAT (Chakravarti et al., 1999; Yang
et al., 1996), CβF-CMV-wildtype c-MYC (FLAG-tagged) and CβF-
CMV-Lys-Arg c-MYC mutants: K323R/K417R and R5 (Faiola et al.,
2005; Patel et al., 2004; McMahon et al., 1998) have been previously
described. The c-MYC R5 combinatorial mutant contains the follow-
ing Lys-Arg substitution mutations: K144R/K149R/K158R/K317R/
K323R (Faiola et al., 2005). All transfections were carried out using
SuperFect (Qiagen) or Lipofectamine-Plus (Invitrogen) reagents as
recommended in the manufacturers' protocols. Luciferase assays
were performed using the Dual-Glo Luciferase Assay System
(Promega, Inc.).
To inhibit endogenous TIP60 protein expression using small
interfering-RNAs (siRNAs), 293A HEK cells were repeatedly
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transfected with increasing amounts (0.25 and 0.5 μg) of a bridged
nucleic acid (BNA) RNA oligonucleotide targeted against tip60
transcripts (siRNA-tip60): 5'-AACCCCUCCACCUUCCGþT-phos-
phorothioate-30, or a non-speciﬁc RNA (nsRNA) BNA oligonu-
cleotide: 50-2-O-methyl-UUACCGAGACCGUACGUA-2-O-methyl-
U-30 (Biosynthesis, Inc.) as a negative control. All RNA transfections
were performed using the HiPerfect transfection reagent (Qiagen,
Inc.) as recommended in the manufacturer's protocol.
Chromatin-immunoprecipitations and dual-ChIPs
Chromatin-immunoprecipitations were performed by cross-
linking c-MYC-containing nucleoprotein complexes in vivo by treating
cultures with 270 μl of 37% formaldehyde for 10 min at 37 1C under 5%
CO2. The cells were pelleted by centrifugation and resuspended in
200 μl SDS-Lysis Buffer (Upstate Biotechnology). Chromatin DNA was
fragmented by sonication, and oligonucleosomal/nucleoprotein com-
plexes were precipitated using primary antibodies and 60 μl salmon
sperm DNA/Protein A-agarose (Upstate Biotechnology). The precipi-
tated complexes were washed, cross-links were reversed, and DNA
fragments were ampliﬁed by PCR using oligonucleotide DNA primers
that anneal to nucleotide sequences that ﬂank conserved E-box
enhancer elements within the human cyclin D2 promoter (prm
primers: 50-CCCCTTCCTCCTGGAGTGAAATAC-30 and 50-CGTGCTCTAA-
CGCATCCTTGAGTC-30); the control utr primers (50-ATCAGACCCTATTC-
TCGGCTCAGG-30 and 50-CAGTCAGTAAGGCACTTTATTTCCCC-30) an-
neal to an untranslated (utr) region of the cyclin D2 gene (Awasthi
et al., 2005; Vervoorts et al., 2003). PCR products were electrophor-
esed through a 2% Tris–acetate-EDTA agarose gel and visualized using
ethidum bromide. Dual-ChIPs were performed using HTLV-1-trans-
formed HuT-102 lymphocytes as described in Vakoc et al. (2005).
Brieﬂy, following the initial immunoprecipitation, nucleoprotein com-
plexes were eluted with 10 mMDTTat 37 1C for 30 min. Samples were
then diluted in ChIP-Dilution Buffer (Upstate Biotechnology) and re-
immunoprecipitated using primary antibodies and 60 μl salmon
sperm DNA/Protein A-agarose. The re-immunoprecipitated complexes
were washed, crosslinks were reversed, and bound DNA fragments
were ampliﬁed by PCR using the prm oligonucleotide primers as
described (Awasthi et al., 2005).
Foci-formation/cellular transformation
To assess cellular transformation by HTLV-1 p30II-GFP (or p30II-
HA) and wildtype c-MYC or the acetylation-defective Lys-Arg c-MYC
K323R/K417R and R5 mutants, 2105 c-myc / HO15.19 rat ﬁbro-
blasts (Albihn et al., 2006; Mateyak et al., 1997) were seeded in
60 mm2 tissue-culture dishes and co-transfected with CβF-wildtype
c-MYC or Lys-Arg c-MYC mutants and CMV-HTLV-1 p30II-GFP or a
pcDNA3.1-GFP control. Transfected cultures were monitored micro-
scopically over a two-week period until transformed colonies were
visible –evidenced by the loss of contact-inhibition and pronounced
cell clustering (Awasthi et al., 2005). The plates were ﬁxed in 70%
ethanol-PBS and stained with methylene blue for improved visualiza-
tion of colonies. DAPI-nuclear staining was also included in certain
experiments to verify cellular foci/nuclear aggregation. The expression
of HTLV-1 p30II-GFP in transformed foci was conﬁrmed by direct
ﬂuorescence-microscopy. Foci-formation experiments using immor-
talized human wrn / WS AG11395 ﬁbroblasts (Moser et al., 2000)
to determine the effects of dominant-negative acetyltransferase
mutants, TIP60Q377E/G380E, p300ΔE1A, and PCAFΔHAT (Ikura et al.,
2000; Chakravarti et al., 1999; Yang et al., 1996), upon HTLV-1
p30II(HA)/c-MYC-induced cellular transformation were performed as
in Awasthi et al. (2005).
Annexin-V-FITC apoptosis assays and BrdU-induced cytotoxicity
Apoptosis was measured in co-transfected c-myc / HO15.19
ﬁbroblasts, expressing the HTLV-1 p30II (HA) and wildtype or
acetylation-defective Lys-Arg c-MYC mutant proteins, by staining
the cultures with Annexin-V-FITC/PI (BD-Pharmingen) and per-
forming ﬂow cytometric analyses on a BD FACSCaliber instrument.
Alternatively, the adherent c-myc / HO15.19 ﬁbroblasts and
HTLV-1 p30II(HA)/c-MYC-transformed colonies were stained with
Annexin-V-FITC and apoptotic cells were visualized and quantiﬁed
by direct ﬂuorescence-microscopy. C2-Ceramide and staurospor-
ine (Sigma-Aldrich) were included as positive apoptosis controls.
To evaluate the effects of HTLV-1 p30II and wildtype c-MYC, or
acetylation-defective c-MYC K323R/K417R and R5 mutants, upon
programmed cell-death induced by prolonged exposure to genotoxic
stress, the co-transfected c-myc / HO15.19 cultures were treated
with bromodeoxyuridine (BrdU) for 12 h. Subsequently, the cells
were washed, ﬁxed/permeabilized and immunostained using an anti-
BrdU-FITC-conjugated antibody. The DNA was stained with 7-AAD
(BD-Pharmingen) and the cells were analyzed by ﬂow cytometry
(Awasthi et al., 2005). Cytotoxicity induced by long-term BrdU-
exposure was observed by staining the co-transfected cultures with
Annexin-V-FITC and apoptosis was quantiﬁed by direct ﬂuorescence-
microscopy.
Detecting c-MYC-acetylation
To observe Lys-acetylation of the c-MYC oncoprotein, 293 HEK
cells were co-transfected with CβF-CMV-c-MYC (FLAG-tagged) in the
presence of increasing amounts of CMV-HTLV-1 p30II-GFP or an
empty vector control. The cells were pelleted by centrifugation at
4 1C, resuspended in RIPA buffer (phosphate-buffered saline, PBS, 1%
v/v IGEPAL-CA630, 0.5% sodium deoxycholate, and 0.1% sodium
dodecyl sulfate, SDS) containing protease inhibitors (antipain dihy-
drochloride, bestatin, leupeptin, aprotinin, chymostatin, and pepstatin
(Roche Applied Sciences)), and lysed by sonication at 70% duty cycle
using a microprobe. Acetylated cellular proteins were immunopreci-
pitated using an anti-Acetyl-Lysine antibody (Millipore)/Protein
G-agarose (Invitrogen), centrifuged and washed, resolved by SDS-
PAGE, and the bound acetylated-c-MYC protein was detected by
immunostaining as in Patel et al., 2004. The status of c-MYC-
acetylation in HTLV-1-transformed HuT-102 and MJG11 T-lympho-
cytes was determined by immunoprecipitating cellular acetylated
proteins using an anti-Acetyl-Lysine antibody/Protein G-agrose. As a
negative IP control, immunoprecipitations were carried out in parallel
using an anti-GFP antibody (Sigma-Aldrich). The acetylated-c-MYC
was detected by immunoblotting as described (Patel et al., 2004).
Uninfected Jurkat E6.1 T-lymphocytes were included as a control.
BrdU-incorporation and lentiviral transductions
To determine if HTLV-1 p30II-expressing cells enter the S-phase
and replicate their genome in the presence of etoposide, HFL1
human ﬁbroblasts (ATCC, CCL-153) were transduced with lenti-
viral particles expressing the HTLV-1 p30II (HA-tagged) protein:
pLenti-6.2/V5-DEST-HTLV-1 p30II HA, or empty pLenti-6.2/V5-
DEST vector particles (Invitrogen, Inc.) as a negative control. The
transduced cultures were treated with etoposide and then labeled
with BrdU for 6 h. The cells were subsequently ﬁxed, permeabi-
lized, and stained using an anti-BrdU-FITC antibody (BD Pharmin-
gen), and immunoﬂuorescence-microscopy was performed to
detect anti-BrdU-FITC-staining in the p30II (HA)-expressing or
vector control transduced cells.
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Statistical analysis
The statistical signiﬁcance and conﬁdence intervals of experi-
mental data sets were analyzed by determining their Student's
t-distribution values (alpha¼0.05).
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